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SUMMARY 
1. Bradykinin (Bk; Argl-Pro2-Pro3-Glya-PheS-Ser6-ProT-PheS-Arg8) in- 
activation by bulk isolated neurons from rat brain is described. 
2. Bk is rapidly inactivated by neuronal perikarya (4.2 + 0.6fmol/min/cell 
body). 
3. Sites of inactivating cleavages, determined by a kininase bioassay combined 
with a time-course Bk-product analysis, were the PheS-Ser 6, Pro7-Phe 8, 
Gly4-Phe 5, and Pro3-Gly 4 peptide bonds. The cleavage of the PheS-Ser 6 bond 
inactivated Bk at least five fold faster than the other observed cleavages. 
4. Inactivating peptidases were identified by the effect of inhibitors on 
Bk-product formation. The PheS-Ser 6 bond cleavage is attributed mainly to a 
calcium-activated thiol-endopeptidase, a predominantly soluble enzyme which did 
not behave as a metalloenzyme upon dialysis and was strongly inhibited by 
N-[l(R,S)-carboyx-2-phenylethyl]-Ala-Ala-Phe-p-aminobenzoate and endo- 
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oligopeptidase A antiserum. Thus, neuronal perikarya thiol-endopeptidase seems 
to differ from endo-oligopeptidase A and endopeptidase 24.15. 
5. Endopeptidase 24.11 cleaves Bk at the Gly4-Phe 5 and, to a larger extent, 
at the Pro7-Phe 8 bond. The latter bond is also cleaved by angiotensin-converting 
enzyme (ACE) and prolyl endopeptidase (PE). PE also hydrolyzes Bk at the 
Pro3-Gly 4 bond. 
6. Secondary processing of Bk inactivation products occurs by (1) a rapid 
cleavage of Ser6-Pro7-PheS-Arg 8 at the Pro7-Phe 8 bond by endopeptidase 24.11, 
3820ACE, and PE; (2) a bestatin-sensitive breakdown of Phe8-Arg9; and (3) 
conversion of Argl-Pro 7 to Argl-Phe 5, of Gly4-Arg 9 to both Gly4-Pro 7 and 
Ser6-Arg 9, and of PheS-Arg 9 to Ser6-Arg 9, Phe8-Arg 9, and Ser6-Pro 7, by 
unidentified peptidases. 
7. A model for the enzymatic inactivation of bradykinin by rat brain 
neuronal perikarya is proposed. 
INTRODUCTION 
Bradykinin (Bk) 4 has been suggested to play a role as a neuromodulator and/or 
neurotransmitter in the CNS (Snyder, 1980; Kariya et al., 1985) on the basis of 
several lines of evidence, such as biological activity, localization and distribution, 
and interaction with a specific receptor. Moreover, all the components of a 
kallikrein-kinin system, which include kallikrein (Chao et al., 1983), kininogen 
(Shikimi et al., 1973), kinin-converting (Camargo et al., 1972), and Bk- 
inactivating (Carvalho and Camargo, 1981; cf. Orlowski, 1983) activities, and Bk 
(Corr~a et al., 1979; Perry and Snyder, 1984; Kariya et al., 1985) have been 
identified in the mammalian CNS. 
Bk is rapidly inactivated after intracerebroventricular injection (half-life, 
26.6 sec) (Kariya et al., 1982), and its major inactivation mechanism appears to 
occur through peptide bond cleavage. Bk neuronal inactivation has been 
approached in vitro using homogenate preparations, purified peptidases, and 
cloned cell cultures, among other systems. Regarding the latter system, two cell 
lines from neural origin (neuro-2a neuroblastoma and C8 glioma clones) were 
recently employed to study Bk inactivation (DelBel et al., 1986). Although cell 
lines can provide useful models to study Bk enzymatic processing, it should be 
pointed out that they represent a transformed cell system. In this study, we have 
employed a preparation of bulk isolated neuronal perikarya (Sellinger et al., 
1971) from rat brain that is essentially devoid of nonneuronal cell types. This 
preparation was used to investigate the enzymatic mechanisms of Bk inactivation. 
MATERIALS AND METHODS 
Materials 
Bk and its fragments were synthesized by Professors A. C. M. Paiva and L. 
Juliano, Escola Paulista de Medicina, Sao Paulo. N-Suc-GIy-Pro-MCA [7-(N- 
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succinyl-glycyl-L-proline)-4-methyl-coumarinamide] and AMC (7-amino-4- 
methyl-coumarin) were from Peptide Institute. Aminex A-5 and Durrum DC-6A 
resins were from Bio-Rad Laboratories and Durrum Chemical, respectively. All 
chemicals used for the amino acid analyzer buffer and ninhydrin solutions were 
from Pierce Chemical. Polyvinylpyrrolidone and bestatin were from General 
Aniline and Film and Sigma Chemical, respectively. Bovine serum albumin was 
fraction V from Pentex. MK 422 (N-[(S)-l-carboxy-3-phenylpropyl]-L-Ala-L-Pro) 
was a gift from Dr. L. J. Greene (Departamento de Farmacologica, Faculdade de 
Medicina de Ribeir~to Pr~to, Universidade de S~o Paulo). Rat brain endo- 
oligopeptidase A antiserum, rabbit IgG fraction (antiserum), was provided by Dr. 
A. C. M. Camargo, Departamento de Farmacologia, Instituto de Ci~ncias 
Biom6dicas, Universidade de S~o Paulo. cf-A-A-F-pAB (N-[l(R,S)-carboxy-2- 
phenylethyl]-L-Ala-L-Ala-L-Phe-p-aminobenzoate) and cF-F-pAB (N-[I (R,S)-  
carboxy-2-phenylethyl]-L-Phe-p-aminobenzoate), as well as Z-Pro-prolinal (N- 
benzyloxycarbonyl-L-prolyl-prolinal), were provided by Drs. M. Orlowski and S. 
Wilk (Department of Pharmacology, Mount Sinai School of Medicine of the City 
University of New York). 
Isolation of Neuronal Perikarya 
Neuronal cell bodies were bulk isolated from brains of 18-day-old rats, 
according to a modification of the procedure of Sellinger et al. (1971). Brains 
from 13 Wistar rats were placed on an ice-cooled plate and cerebral cortices were 
dissected. The tissue (8.6 g wet weight) was minced using a razor blade, and 8.1 g 
was transferred into 120ml ice-cold 7.5% (w/v) polyvinylpyrrolidone solution 
containing 1% (w/v) bovine serum albumin and 10 mM CaCIa (solution I). The 
mince was sieved through nylon bolting cloth (Tobler, Ernest and Traber, 
Elmsford, N.Y.) of 333-, 110- and 73-/urn pore size. The volume of the last filtrate 
was brought to 130 ml with ice-cold solution I. Aliquots (20 ml) of the filtrate 
were layered on a two-step gradient (7 ml 1.0 M sucrose and 6 ml 1.75 M sucrose) 
and centrifuged at 41,000g for 30 min at 4°C, using a Beckman SW27 rotor. The 
pellet consisted of purified neuronal perikarya and its purity was assessed by 
phase-contrast microscopy. In fields comprising more than 50 structured particles, 
about 90% were neuronal perikarya. Contaminating structures consisted of bare 
nuclei and occasional capillary threads. Glial cells were not detected. Neuronal 
perikarya yield was (4.45:0.45)× 106cells/g wet brain cortex (mean+SE;  
N = 5). Each neuronal pellet was either suspended in 2.0ml/pellet of 0.05 M 
Tris-HC1 buffer, pH 7.5, containing 0.32M sucrose, and homogenized using a 
Potter-Elvehjem homogenizer for use on the same day or rapidly frozen to 
-70°C, stored at -20°C, and used within 1 week. Soluble and particulate 
fractions were prepared by centrifuging the homogenate at 105,000g for 1 hr at 
4°C. 
Prolyl Endopeptidase Assay 
Prolyl endopeptidase (PE) activity was determined by a modification 
(Martins et al., 1987) of the procedure of Kato et al. (1980). Initial rates (two or 
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three time points) of AMC release were measured by incubating 3.3mM 
N-suc-Gly-Pro-MCA with the neuronal perikarya homogenate or homogenate- 
derived fraction in 100 #1 0.05 M Tris-HC1 buffer, pH 7.5, containing 0.1 M NaC1 
and 2 mM dithiothreitol (DTT), at 37°C for up to 30 min. The homogenate was 
preincubated with 2 mM DT-F at 37°C for 5 min before the addition of substrate. 
The reaction was stopped by the addition of 2.0 ml 1.0 M sodium acetate buffer, 
pH 4.2, per 100 #1 incubation medium. AMC was determined with an Aminco 
Model 125 spectrophotofluorometer at 380-nm excitation and 460-nm emission 
wavelengths on the supernatant (8300g for 10 min) of the acidified incubation 
medium. Blanks were prepared in the same manner as the incubates, except that 
1.0 M sodium acetate buffer, pH 4.2, was added before the homogenate (zero 
time of reaction). Standard curves (0.3-3.0 nmol AMC/100/~1) presented a linear 
relationship between fluorescence intensity and AMC concentration. Homogen- 
ate (up to 50 #1) did not change the standard curve slope. In experiments 
designed to determine adequate assay conditions for measuring rat brain PE 
activity, it was shown that PE specific activity in a brain homogenate was maximal 
at a 2.5mM substrate concentration. AMC release was linearly related to 
incubation time from 10 to 120 min, for 11-82/zg homogenate protein, and PE 
specific activity was independent of homogenate protein concentration in the 
above range. All measurements were carried out in duplicate. PE specific activity 
is expressed as nanomoles of AMC released per minute per milligram of protein. 
Kininase Bioassay 
The kininase bioassay (Camargo et al., 1972) measures the rate of hydrolysis 
of the first peptide bond cleaved in Bk, because the hydrolysis of any peptide 
bond in the molecule leads to products essentially devoid of spasmogenic activity 
upon the isolated guinea pig ileum (Suzuki et al., 1969). Initial Bk inactivation 
rates (two to four time points) were measured incubating 116 ~M Bk with a 
neuronal homogenate or homogenate-derived fraction in 250 or 1000/~1 0.05 M 
Tris-HCl buffer, pH 7.5, containing 0.1 M NaC1, at 37°C, for up to 60 min. The 
reaction was stopped by the addition of a 50-~1 aliquot of the incubation medium 
to 0.95 ml 20 mM HC1. Residual Bk was determined with the isolated guinea pig 
ileum bathed in 10ml Tyrode buffer containing 0.14/~M atropine and 0.17/zM 
diphenhydramine at 37°C. Controls were prepared in the same manner as the 
incubates, except that HCI was added before the homogenate (zero time of 
reaction). Control experiments showed that Bk was stable in the presence of 
acidified neuronal homogenate for up to 24hr and that the incubation of 
homogenate in 0.05 M Tris-HC1 buffer, pH 7.5, containing 0.1 M NaCl, without 
Bk, at 37°C for up to 2hr did not lead to the release of material having 
spasmogenic activity upon the isolated guinea pig ileum. In experiments designed 
to determine adequate assay conditions for the measurement of rat brain kininase 
activity, it was shown that kininase activity was maximal at 100/zM Bk. Bk 
inactivation was linearly related to incubation time from 5 to 180rain, for 
30-640/~g homogenate protein, and kininase specific activity was independent of 
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homogenate protein concentration over a 20-fold range. All measurements were 
carried out in duplicate. Kininase specific activity is expressed as nanomoles of Bk 
inactivated per minute per milligram of protein. 
Bradykinin-Product Analysis 
An amino acid analyzer was used to determine Argl-Pro 3, Argl-Gly 4, 
Argl-Phe 5, Argl-Pro 7, Gly4-Arg 9, PheS-Arg 9, Ser6-Arg 9, PheS-Arg 9, and 
Gly4-Pro 7 (Oliveira et al., 1976). Free amino acids were measured by the method 
of Spackman et al. (1958). The incubation conditions used for Bk-product analysis 
were similar to those used for the kininase bioassay, unless otherwise stated~ and 
the reactions were stopped by the addition of 1.2 ml/ml incubation medium of a 
solution containing 69% (v/v) 0.2 M sodium citrate, pH 2.2, 1% (v/v) 6 M HC1 
and 30% (v/v) polyethylene glycol 400. Sample cleanup before amino acid and 
peptide analysis was carried out by filtration of the hydrolysate supernatant 
(8300g for 10 min) through a 0.45-#m filter (Millipore). The values reported for 
free amino acids were corected for the blank values obtained by incubating the 
homogenate or homogenate-derived fractions with or without peptidase inhibitors 
but without Bk. Control experiments showed that homogenate did not release 
material that eluted with the elution volume of the peptide standards. 
Dialysis 
Dialysis tubing (8/32 Nojax Visking Casing) was freed from contaminating 
substances according to the procedure of McPhie (1971). Water was purified 
using a four-cartridge Milli-Q system (Waters). Purified water (resistivity 
->10Mf2-cm) showed the following metal concentration (g/liter), measured by 
atomic absorption spectrophotometry, <4.5 × 10 -8, zinc, and 1.1 × 10 -7, calcium, 
and was used for the preparation of all solutions. The neuronal perikarya-soluble 
fraction was treated as described in the legend to Fig. 4. 
DNA Determination 
DNA was measured by the procedure of Croft and Luban (1965), using 
highly polimerized calf thymus DNA (California Corp. Biochemical Research) as 
the standard. 
Protein Determination 
Protein was measured by a modification (Bensadoun and Weinstein, 1976) of 
the method of Lowry et al. (1951), using bovine serum albumin as the standard. 
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RESULTS 
Time Course of Bradykinin-Product Formation 
The only peptide products detected at 10 min of Bk inactivation by the 
neuronal perikarya homogenate (Fig. 1A) were the complementary fragments 
Argl-Phe51 Ser6-nrg9, Argl-Pr07 I Phe8-Arg9, and Argl-Gly41 PheS-Arg 9. At 
this time (about 10% bradykinin inactivation), the stoichiometry of the com- 
plementary peptide products Argl-Phe51 Ser6-Arg8 and ArgO-Pro7 I PheS-Arg9 
was essentially 1:1, whereas ArgLGly  4 and PheS-Arg 9 were recovered in the 
molar proportion 1:0.2. The recovery of the hydrolysis products accounted for 
117% of the Bk inactivated. These results indicate that isolated neurons 
hydrolyze Bk at the PheS-Ser 6, Pro7-Phe 8, and Gly4-Phe 5 peptide bonds. The 
initial rate of PheS-Ser 6 bond cleavage was about five fold higher than that of the 
Pro7-Phe 8 and Gly4-Phe 5 bonds. At >10% Bk inactivation, low amounts 
(<0.05mol/mol Bk inactivated) of Gly4-Arg 9, Gly4-Pro 7, and Ser6-Pro 7 
were detected, whereas the low-color yield peptide Argl-Pro 3, which is comple- 
mentary to Gly4-Arg 9, was detected only at 40 and 60 min of incubation 
(<0.05 mol/mol Bk inactivated). These results suggest that isolated neurons 
also hyrolyze Bk at the Pro3-Gly 4 bond. 
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Fig. 1. Time course of Argl-Proa-Pro3-Gly4-PheS-Ser6-Pro7-PheS-Arg 9 (bradykinin) 
hydrolysis by a neuronal perikarya homogenate. Bradykinin (176 ~M) was incubated with 
200/ul (21/~g DNA) homogenate in 1.0ml 0.05M Tris-HCl buffer, pH7.5, containing 
0.1 M NaC1, at 37°C for up to 60 min. The reaction was stopped at the indicated times by 
acidification. Residual bradykinin was determined by bioassay. Bradykinin fragments and 
amino acids were measured using an amino acid analyzer. (A) Peptides: A /X, 
1 5 6 9 1 7 8 9 A r g - P h e  ; • A,  S e r - A r g  ; O O, A r g - P r o  ; O------O, Phe -Arg  ; [] I-q, 
Argl_Gly4; m I ,  PheS-Arg9; . . . .  , bradykinin. (B) Amino acids: O-----O, Arg; 
O O, Phe; [] I-q, Ser; A A, Pro; • • ,  Gly. 
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The rates of release of arginine and, to a lesser extent, phenylalanine during Bk 
inactivation (Fig. 1B) were much higher than those of glycine, serine, and 
proline. The profile of free amino acids released from Bk by isolated neurons is 
similar to that by neuro-2a neuroblastoma but not to that by C8 glioma cells 
(DelBel et al., 1986). 
Processing of BK Hydrolysis Products 
The increase in the relative amounts of free amino acids during Bk 
inactivation (Fig. 1B), concomitantly with a variation of the rate of release and a 
loss of the 1: 1 stoichiometry of the complementary peptide products (Fig. 1A), 
was due to proteolytic processing of the primary hydrolysis products, possibly by 
endopeptidases and exopeptidases. Indeed, Table I shows that, in addition to the 
release of free amino acids, isolated neurons catalyzed the conversion of some 
primary inactivation products into shorter-chain primary and secondary peptide 
products. Thus, Argl-Pro 7 was extensively degraded to Argl-Phe 5 and, to a 
lesser extent, to Ser6-Pro 7 and Gly4-Pro 7. The major peptide fragments formed 
from Gly4-Arg 9 were Ser6-Arg 9 and Glya-Pro 7, and that from PheS-Arg 9 was 
Ser6-Arg 9. Ser6-Arg 9 and Phe8-Arg 9 were almost completely degraded to free 
amino acids. At incubation times shorter than 30 min, in addition to free amino 
acids, Ser6-Pro 7 and PheS-Arg 9 were released from Ser6-Arg 9 by neuronal 
perikarya homogenate (data not shown), indicating that the homogenate 
hydrolyzes the Pro-Phe bond of Ser-Pro-Phe-Arg.  In general, the N-terminal 
products of Bk inactivation were more resistant to degradation than the 
C-terminal fragments, possibly due to their Pro-Pro moiety. 
Effect of Peptidase Inhibitors on Bk Processing 
Table II shows that the metal chelator 1,10-phenanthroline exhibited a 
concentration-dependent inhibition of kininase activity, which was 93% inhibited 
by 1 mM chelator. In contrast, the other chelators used exerted either a slight 
(1 mM 8-hydroxyquinoline) or no (1 mM EDTA and 1 mM EGTA) inhibitory 
effect on kininase activity. PE activity was affected in the same manner as 
kininase activity by metal chelators. DTT (up to 2 mM) did not appreciably affect 
kininase activity, while it slightly activated PE activity. Both activities were 
strongly inhibited by 1 mM PCMB. The serine protease inhibitor diisopropyl- 
fluorophosphate (DFP; 0.2 mM) inhibited 7 and 99% kininase and PE activities, 
respectively, cF-Ala-Ala-Phe-pAB,  an inhibitor of endopeptidase 24.15 (Chu 
and Orlowski, 1984), presented a concentration-dependent inhibition of kininase 
activity (data not shown), which was 90% inhibited by i mM inhibitor. Maximal 
inhibition (75%) of kininase activity by antiserum was attained at 16/~1 
antiserum/ml incubation medium. Z-Pro-prolinal (10/zM), a PE inhibitor (Wilk 
and Orlowski, 1983), inhibited 98% neuronal perikarya PE but did not 
appreciably affect kininase activity. Bestatin (50/~M), an aminopeptidase in- 
hibitor, did not affect kininase activity. 
Table III shows that 1,10-phenanthroline exhibited a concentration- 
dependent inhibitory effect on the release of the complementary peptide products 
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Table II. Effect of Peptidase Inhibitors on Neuronal Perikarya 
Kininase and Prolyl Endopeptidase Activities a 
Kininase activity PE activity 
Inhibitor (%) (%) 
None 100 100 
0.1 mM 1,10-phenanthroline 62 nd 
1.0 mM 1,10-phenanthroline 7 20 
0.1 mM 8-hydroxyquinoline 106 106 
1.0 mM 8-hydroxyquinoline 80 80 
1.0 mM EDTA 103 107 
1.0 mM EGTA 103 106 
2.0 mM dithiothreitol 110 125 
1.0 mM PCMB 13 2 
0.2 mM DFP 93 1 
1.0 mM cF-Ala-Ala-Phe-pAB 10 nd 
8/~1 antiserum 25 nd 
10/~M Z-Pro-prolinal 97 2 
50/~M bestatin 107 nd 
a The homogenate was preincubated (15 min, 37°C) with or without 
(control) inhibitor in 0.5 ml 0.05 M Tris-HC1 buffer, pH 7.5, 
containing 0.1 M NaCI, and incubation (up to 30 min, 37°C) was 
started by the addition of either l16#M bradykinin (kininase 
assay) or 3.3 mMN-suc-Gly-Pro-MCA (PE assay). The incuba- 
tions were stopped by acidification. Kininase and PE activities were 
determined by bioassay and fluorimetry, respectively. The average 
values of four (kininase) and two (PE) determinations, which 
differed by 20% or less and 6% or less, respectively, are reported. 
Antiserum, endo-oligopeptidase A antiserum; nd, not determined. 
Arg l -PheS lSe r6 -Arg  9 and Argl-Pr07 ]PheS-Arg 9 and of Ser6-Pro 7 and free 
amino acids from BK. The formation of peptide products was essentially 
abolished by 1 mM 1,10-phenanthroline. E D T A  (1 .0mM) and DFP (0 .2mM) 
did not inhibit the formation of A r g l - P h e  5 [ Ser6-Arg 9 but partially blocked that 
of Argl-Pr07 [ PheS-Arg 9, Ser6-Pro 7, and free amino acids. The formation of 
Argl-Phe5 [ Ser6-Arg 9 was essentially abolished by 0.1 mM PCMB, while the 
release of ArgX-Pro 7 was about 2.5-fold increased and that of PheS-Arg 9, 
SerS-Pro 7, and free amino acids decreased. The PCMB inhibition of Arg 1- 
Phe5 [ Ser6-Arg 9 release was almost completely reversed by 0.5 mM DTF,  and 
that of PheS-Arg 9, Ser6-Pro 7, and free amino acids was partially reverted,  but 
the formation of ArgO-Pro 7 was strongly inhibited, c F - A I a - A l a - P h e - p A B ,  an 
inhibitor of the soluble (Chu and Orlowski, 1984) and membrane-bound (Acker 
et al.,  1987) forms of endopeptidase 24.15 blocked the release of Arg ~- 
PheSlSer6-Arg  9 in a concentrat ion-dependent  manner  (inhibition >90% by 
l mM inhibitor), whereas the concentration of Arg l -P ro  7 increased up to 
5.2-fold, and that of Phe8-Arg 9, Ser6-Pro 7, and free amino acids decreased as the 
inhibitor concentration increased. Rat  brain endo-oligopeptidase A antiserum, 
which exhibits anticatalytic activity against endo-oligopeptidase A (Camargo et 
al., 1987; Toffoletto et al.,  1988), strongly blocked the release of Arg 1- 
Phe 5 ] Ser6-Arg 9, increased twofold the concentration of Arg l -P ro  7, and 
decreased that of PheS-Arg 9, Ser6-Pro 7, and free amino acids. A twofold 
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increase in antiserum concentration did not lead to a further decrease in 
Argl-Phe5 I Ser6-Arg 9 formation. Endopeptidase 24.11 inhibitor cF-Phe-pAB 
(0.1 raM) (Almenoff and Orlowski, 1983) strongly inhibited the formation of 
Argl-Pro 7, PheS-Arg 9, Ser6-Pro 7, and free amino acids but increased 21% the 
Ser6-Arg 9 concentration without affecting that of Arg~-Phe 5. MK 422 and 
Z-Pro-prolinal, inhibitors of ACE (Patchett et al., 1980) and PE (Wilk and 
Orlowski, 1983), respectively, exhibited inhibitory effects on the release of Bk 
fragments which were qualitatively similar to those of cF-Phe-pAB, but less 
intense, except that the Ser6-Arg 9 concentration was not affected or decreased 
slightly. MK 422 (0.1 mM) and Z-Pro-prolinal (10 #M) blocked 56 and 40% 
respectively, the formation of ArgX-Pro 7. 
Effect of Peptidase Inhibitors on Ser-Pro-Phe-Arg Degradation 
Ser6-ProT-Phe8-Arg 9, which is one of the primary products of Bk inactiva- 
tion, contains the Pro-Phe bond that was primarily cleaved in Bk (cf. Fig. 1A) 
and was extensively degraded by the neuronal perikarya homogenate (cf. Table 
1). Therefore, we have studied the effect of peptidase inhibitors on the 
proteolytic processing of this tetrapeptide by the neuronal homogenate. Figure 2, 
left, shows that 50/~M bestatin led to a sixfold increase in Phe-Arg release, 
while the phenylalanine and arginine concentrations decreased 94 and 78%, 
respectively. These results indicate that the hydrolysis of Phe-Arg was catalyzed 
to a large extent by a bestatin-sensitive aminopeptidase. Since arginine release 
was 4.4-fold higher than that of phenylalanine in the presence of bestatin, the 
involvement of a carboxypeptidase in arginine release from Ser6-Arg 9 cannot be 
excluded. The effect of peptidase inhibitors on Pro-Phe bond hydrolysis was 
studied by measuring the release of Phe-Arg from Ser6-Pro7-PheS-Arg9 in the 
presence of 50/tM bestatin. Figure 2, right, shows that with 50/~M bestatin, the 
formation of Phe-Arg from Ser6-Arg 9 was 52, 27, and 22% inhibited by 0.1 mM 
cF-Phe-pAB, 0.1 mM MK 422, and 0.1 mM Z-Pro-prolinal,  respectively. A 
mixture of these four inhibitors, at the above concentrations, abolished the 
release of Phe-Arg. 
Characterization of the Major Bradykinin-lnactivating Endopeptidase 
Activity in Neuronal Perikarya 
Occurrence in the Neuronal Soluble Fraction 
Table IV documents the levels of kininase and PE activites in isolated 
neurons. The values of kininase and PE specific activities in the neuronal 
perikarya homogenate corresponded to 4.2 + 0.56 and 0.4 + 0.07 (aveage +SE; 
N = 9), respectively, when expressed as femtomoles per minute per cell body. 
The yields of kininase and PE activities in the neuronal perikarya homogenate 
(relative to brain cortex, taken as 100%), were 1.9 +0.2% and 0.4+0.05% 
(N = 9), respectively. Kininase activity recovery was 1.7-fold higher in the soluble 
(105,000g for i hr) than in the particulate fraction, whereas the distribution of PE 
activity was about the same in these fractions. These results suggest that 
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Fig. 2. Effect of peptidase inhibitors on Se r -P ro -Phe -  
Arg degradation by a neuronal perikarya homogenate. 
The homogenate was preincubated (15 min, 37°C) with or 
without inhibitor, in 0.05 M Tfis-HCI buffer, pH7.5,  
containing 0.1 M NaC1, and incubation (30min, 37°C) 
was started by the addition of 54/~M Ser-Pro-Phe-Arg .  
The reaction was stopped by acidification. Degradation 
products were determined using an amino acid analyzer. 
Left: effect of bestatin on the release of Phe-Arg,  Phe, 
and Arg from Ser -Pro-Phe-Arg .  Hatched bars, no 
inhibitor; open bars, 50/~M bestatin. Right: effect of 
inhibitor combinations containing bestatin on Phe-Arg 
release from Ser -Pro-Phe-Arg .  The amount of Phe-Arg 
released is reported as the percentage of that formed in 
the presence of 50/~M bestatin alone (B), taken as 
100%. Inhibitor combinations used were 50/tM bestatin 
and 0.1 mM cF-Phe-pAB (F), 0 .1mM MK 422 (M), 
0.1 mM Z-Pro-prol inal  (Z), and a mixture of all these 
inhibitors at the above concentrations (BFMZ). The 
amounts of free amino acids released in the presence of 
inhibitor combinations were too low for accurate deter- 
mination, and therefore their corresponding values are 
not shown. 
Table IV. Specific Activity and Recovery of Kininase and Prolyl Endopeptidase 
Activities in Neuronal Perikarya Homogenate and Homogenate-Derived Fractions a 
Kininase activity Prolyl endopeptidase activity 
Sp act Recovery Sp act Recovery 
Fraction (nmol/min/mg protein) (%) (nmol/min/mg protein) (%) 
Homogenate 5.7 + 0.3 I100l 0.48 + 0.04 11001 
Soluble 5.7 + 0.5 63 + 9.1 0.42 + 0.04 52 + 4.5 
particulare 4.5 + 1 37 + 9 0.60 + 0.9 48 + 4.9 
a Kininase and prolyl endopeptidase activities were measured by bioassay and fluorimetry, 
respectively. Recoveries are reported relative to the total recovered activity 1100% I in 
the soluble and particulate fractions. The yields relative to homogenate for kininase and 
prolyl endopeptidase activities were 121 and 119%, respectively. The average values 
+SE of five independent determinations are reported. 
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neuronal perikarya kininase activity is mainly cytosoluble, in agreement with 
subcellular distribution studies carried out with whole brain (Camargo and 
Graeff, 1969). However, kininase activity is predominantly particulate in ex- 
ponentially growing neuro-2a neuroblastoma cells (DelBel et al.,  1986). Neuronal 
PE activity is not predominantly cytosoluble, in contrast to the enzyme 
distribution reported using whole brain (Dresdner et al.,  1982) but not to that 
described in neuro-2a neuroblastoma cells (DelBel et al.,  1986). 
A product-analysis of Bk degradation by soluble and particulate fractions of 
isolated neurons (data not shown) showed that the peptide- and amino acid- 
product composition of their hydrolysates was similar to that of the parent 
homogenate. The PheS-Ser 6 bond cleavage accounted for more than 95% of Bk 
inactivation by the soluble fraction, on the basis of the relative amounts of the 
complementary peptide products formed. Taken together, the above results and 
the data in Table IV suggest that the major neuronal Bk inactivating cleavage is 
catalyzed by a cytosoluble endopeptidase activity which hydrolyzes the PheS-Ser 6 
peptide bond. 
Effect of Peptidase Inhibitors 
The susceptibility of the Phes-Ser 6 bond hydrolysis by the soluble neuronal 
fraction to peptidase inhibitors was studied next. Figure 3 shows that 0.5 mM 
D T r  did not affect the release of the complementary peptide products Arg 1- 
Phe 5 [ Ser6-Arg 9 from Bk, whereas 0.1 mM PCMB inhibited 97% the formation 
of these products. The inhibition of the Phes-Ser 6 bond cleavage by 0.1 mM 
PCMB was surmountable by 0.5 mM DTI'. Kininase activity in a soluble fraction 
dialyzed against 1.0 mM Tris-HC1 buffer, pH 7.0, for 48 hr at 4°C, was activated 
by DTT in a concentration-dependent manner (data not shown). Activation was 
maximal (about twofold) at 0 .5mM DTI? and decreased with higher DTT 
concentrations. At 2 .0mM DTI" there was essentially neither activation nor 
inhibition of enzyme activity. These results indicate a requirement of a thiol 
group for enzyme activity. DFP (0.2mM) did not affect the endopeptidase 
activity. Chelating agents differentially affected the PheS-Ser 6 bond cleavage. 
Thus, 1,10-phenanthroline exhibited a concentration-dependent inhibitory effect 
(>90% inhibition by 1.0mM), whereas EDTA (1.0mM) did not affect the 
peptidase activity. Both cF -Ala -Ala -Phe -pAB and antiserum inhibited the 
Phes-Ser 6 bond hydrolysis in a concentration-dependent manner, and the activity 
was about 90% blocked by 1.0 mM inhibitor and 20 ~tl antiserum/ml. 
Effect of Metal Ions 
Since metal chelators differentially effected the PheS-Ser 6 bond cleavage 
(Table III and Fig. 3), it was not clear whether or not this enzyme activity is 
metal dependent. In order to address this issue, the effect of dialysis of the 
neuronal soluble fraction against 1,10-phenanthroline and EDTA and against 
chlorides of divalent cations on kininase activity was studied. PE activity was also 
studied because the brain enzyme has been shown not to be a metalloprotease 
(cf. Orlowski, 1983); it occurs in the neuronal soluble fraction (cf. Table IV) and 
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Fig. 3. Effect of peptidase inhibitors on the formation of Argl-Phe 5 (IS]) and Ser6-Arg 9 (7~) 
from bradykinin by a neuronal perikarya-soluble fraction. The soluble fraction was preincub- 
ated (15 min, 37°C) with or without (C, control) inhibitor, in 250/d (antiserum tubes) or 1.0 ml 
0.05M Tris-HCl buffer, pH7.5, containing 0.l M NaCI, and incubation (30min, 37°C) was 
started by the addition of 116/zM bradykinin. The reaction was stopped by acidification. The 
1 5 6 9 concentrations of Arg -Phe and Ser -Arg released are reported as the percentage of those 
formed without inhibitor (39 and 31nmol/ml, respectively), taken as 100%. Inhibitor 
concentrations are reported as millimolar, except for those of antiserum, which are reported as 
microliters of antiserum per 250/ul of incubation medium. In a control experiment, it was 
shown that the concentrations of PCMB and DTF used here were the lowest concentrations 
that, upon preincubation (15min, 37°C), essentially fully inhibit (0.1mM PCMB) and 
completely restore (0.5 mM DTT) the PCMB-inhibited kininase activity in a neuronal soluble 
fraction, oP, 1,10-phenanthroline; antiserum, rat brain endo-oligopeptidase A antiserum. 
is affected by metal  chelators (cf. Table II)  similarly to the soluble endopept idase  
activity which hydrolyzes the PheS-Ser 6 bond of Bk (cf. Fig. 3). Figure 4A shows 
that the complete  inhibition of the kininase activity in the soluble fraction by 
dialysis against 1.0 m M  1,10-phenanthroline was more  than 95% reverted upon 
removal  of the chelator by dialysis against 1 m M  Tr i s -HCl  buffer, p H  7.0; these 
dialysis procedures led to about  a 20% decrease in PE activity. In contrast  (cf. 
Fig. 4B), kininase activity was not affected by dialysis against 1 m M  E D T A ,  
whereas PE activity was about  40% activated. Figure 4A also shows that dialysis 
of the 1,10-phenanthroline-treated soluble fraction against 0.1 m M  CaCI2 led to 
33 and 48% activation of kininase and PE activities, respectively, whereas dialysis 
against 0.1 m M  COC12 did not essentially affect or only slightly activated both 
kininase and PE activities. ZnCIa (0.1 mM)  led to about  55% inhibition of both 
enzyme activities. The removal  of excess and loosely bound metal  ions by dialysis 
against 1.0 m M  Tris-HC1 buffer, p H  7.0, essentially reverted the activating and 
inhibitory effects of metal  ions on kininase activity, whereas PE activation by 
CaCI2, but not inhibition by ZnCI~, was reverted. 
Similar experiments,  except that 1 . 0 m M  E D T A  replaced 1 . 0 m M  1,10- 
phenanthroline,  led to comparable  results with respect to the metal  ion effect 
(data not shown). Alternatively,  the neuronal  soluble fraction was dialyzed 
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Fig. 4. Effect of dialysis against chelating agents and metal ions on 
kininase ([]) and prolyl endopeptidase (El) activities in a neuronal 
perikarya-soluble fraction. Kininase and PE activities in each 
dialysis-treated soluble fraction are reported relative to their specific 
activities in a soluble fraction dialyzed for the same time against 
1.0 mM Tris-HCl buffer, pH 7.0 (controls), which were taken as 
100%. Kininase and PE activities were determined (in the presence 
of 0.5 and 2.0 mM dTT, respectively) by bioassay and fluorimetry, 
respectively. (A) Soluble fraction (5.0ml) was dialyzed at 4°C 
against four changes of 500ml 1.0mM 1,10-phenanthroline in 
1.0 mM tris-HCl buffer, pH 7.0, for 24 hr (D1), and then against 
four changes of 500 ml 1.0 mM Tris-HC1 buffer, pH 7.0, for 24 hr 
(D2). The resulting retentate was divided in three equal parts. Each 
part was dialyzed against two changes of 250 ml of 0.1 mM CaCI 2, 
or 0.1 mM COC12, or 0.1 mM ZnCI z in 1,0mM Tris-HCl buffer, 
pH 7.0, for 24 hr (D3), and then against six changes of 250 ml of 
1.0 mM Tris-HCl buffer, pH 7.0, for 48 hr (D4). (B) Same proce- 
dure as for D1 in A, except that 1.0 mM EDTA was substituted for 
1.0 mM 1,10-phenanthroline (DI*). 
against 1.0 mM EDTA, pH 7.0, and then against 1.0 mM Tris-HC1 buffer, pH 
7.0. The preincubation (15 min, 37°C) of this EDTA-treated fraction with 1.0 mM 
CaCI2 or with 25 ~tM ZnC12 led to 60% activation or 40% inhibition of kininase 
activity, respectively. 
DISCUSSION 
The present study shows that rat brain neuronal perikarya contain peptidases 
able to inactivate Bk through hydrolysis of the PheS-Ser 6, ProT-Phe 8, Gly4-Phe s, 
and Pro3-Gly 4 peptide bonds (cf. Fig. 1 and Results). There is strong evidence 
that each of the four inactivating cleavages of Bk by the neuronal perikarya 
homogenate was catalyzed by a different peptidase, except for the Pro7-Phe 8 
bond cleavage, which appears to be catalyzed by at least three enzymes. 
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Neurnal Perikarya Inactivate Bradykinin Mainly Through Cleavage at 
the PheS-Ser 6 Bond by a ThioI-Endopeptidase 
The hydrolysis of Bk at PheS-Ser 6 bond by the neuronal homogenate 
appears to be catalyzed mainly by an endopeptidase different from the multi- 
catalytic protease complex (Wilk and Orlowski, 1980), endopeptidase 24.15 
(Orlowski et al., 1983), and endo-oligopeptidase A (Camargo et al., 1973; 
Carvalho and Camargo, 1981), which hydrolyze the PheS-Ser 6 bond. Evidence to 
support this is as follows. The multicatalytic protease complex is strongly 
inhibited by 1 mM NaCI (Wilk and Orlowski, 1980) and in our enzyme assays 
100 mM NaC1 was employed. The active site-directed inhibitor of endopeptidase 
25.15, cF -Ala -Ala -Phe -pAB (1 mM) (Chu and Orlowski, 1984), which does not 
inhibit endo-oligopeptidase A (Toffoletto et al., 1988), almost completely inhibits 
the Phes-Ser 6 bond cleavage by the neuronal homogenate. Rat brain endo- 
oligopeptidase A antiserum, which exhibits anticatalytic and immunoprecipitating 
activity against endo-oligopeptidase A, but does not similarly affect endopep- 
tidase 24.15 (Toffoletto et al., 1988), strongly inhibits the PheS-Ser 6 bond 
hydrolysis by the neuronal homogenate. Endo-oligopeptidase A (Camargo et al., 
1987) and endopeptidase 24.15 (Orlowski et al., 1983) are strongly inhibited by 
both l mM 1,10-phenanthroline and 1 mM EDTA, whereas the release of 
Arg 1-Phe5 [ Ser6-Arg 9 from Bk by the neuronal homogenate is blocked by 1 mM 
1,10-phenanthroline but not by 1 mM EDTA (cf. Table Ill). The hydrolysis of 
the PheS-Ser 6 bond seems to be catalyzed by a thiol-endopeptidase (cf. Table 
III). Endo-oligopeptidase A (Oliveira et al., 1976; Camargo et al., 1987), but not 
endopeptidase 24.15 (Orlowski et al., 1983; Acker et al., 1987), has been 
reported as a thiol-endopeptidase. 
Argl-Phe 5 is also a degradation product of Argl-Pro 7 by neuronal perikarya 
homogenate (cf. Table I). The inhibition of Bk PheS-Ser 6 bond cleavage by 
cF-Ala -Ala -Phe-pAB,  antiserum, and PCMB leads to a concomitant several- 
fold increase in Argl-Pro 7 formation (cf. Table III), suggesting that the same 
enzyme activity catalyzes the PheS-Ser 6 bond cleavage both of Bk and of its 
ArgX-Pro 7 moiety. Endo-oligopeptidase A does not hydrolyze Argl-Pro 7 to an 
appreciable extent (Oliveira et al., 1976). 
About two-thirds of the neuronal kininase activity is soluble, and more than 
95% of Bk inactivation by the soluble fraction is accounted for by cleavage of the 
Phes-Ser 6 bond (cf. Table IV and Results). Our studies on the effect of 
peptidase inhibitors upon the release of Argl-Phe51 Ser6-Arg9 from Bk by the 
neuronal soluble fraction (cf. Fig. 3) provide strong evidence that a thiol- 
endopeptidase inactivates Bk through cleavage of the PheS-Ser 6 bond and that 
this enzyme differs from previously described soluble peptidases which hydrolyze 
Bk at the same site. Thus, the nearly complete inhibition of the Phes-Ser 6 bond 
cleavage b y  0 .1mM PCMB was fully reversed by 0 .5mM DTF, a DTT 
concentration that maximally activates the peptidase in a dialyzed soluble 
fraction. Both antiserum and c f -Ala -Ala -Phe -pAB almost completely inhibit 
thiol-endopeptidase activity in the neuronal perikarya soluble fraction. 
The differential inhibitory effect of metal chelators on the PheS-Ser 6 bond 
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cleavage exhibited by the neuronal perikarya homogenate (cf. Tables II and III) 
is also displayed by the soluble fraction (cf. Fig. 3): the PheS-Ser 6 bond cleavage 
is blocked by 1 mM 1,10-phenanthroline, but not by 1 mM EDTA, as it occurs 
with carboxypeptidase B (Folk et al., 1960), a metalloenzyme sensitive to 
1,10-pnenanthroline but not to EDTA. However, peptidases reported as non- 
metalloenzymes, such as endo-oligopeptidase A (Camargo et al., 1987) and PE 
(Andrews et al., 1980), can be inhibited by metal chelators. By using a 
dialysis-based technique (Vallee et al., 1960), it was shown (cf. Fig. 4 and 
Results) that the inhibition of soluble neuronal kininase and PE activities by 
1,10-phenanthroline is fully reversible upon removal of the chelator. In contrast 
to endopeptidase 24.15 (initially called soluble metalloendopeptidase), whose 
activity is abolished by dialysis against 1 mM EDTA at pH 7 and restored by the 
addition of Zn 2+ (Orlowski et al., 1983), the EDTA-treated neuronal soluble 
activity is inhibited by Zn 2+. Thus, it seems clear that the thiol-endopeptidase 
activity described here cannot be classified as a metalloendopeptidase. However, 
soluble thiol-endopeptidase activity is activated by high Ca 2÷ concentrations, 
suggesting a possible role of calcium in the regulation of this activity. The 
evidence presented here suggests that neuronal perikarya thiol-endopeptidase 
activity differs from that of both endo-oligopeptidase A and endopeptidase 24.15, 
which were reported to be two different enzymes (Camargo et al., 1987; 
Toffoletto et al., 1988). Our data do not permit excluding a minor contribution of 
endo-oligopeptidase A and/or endopeptidase 24.15 to the cleavage of the Bk 
Phes-Ser 6 bond by neuronal perikarya. 
Involvement of Endopeptidase 24.11, Angiotensin-Converting Enzyme, and 
Prolyl Endopeptidase in BK Neuronal Inactivation 
Bk inactivation by the neuronal perakarya homogenate through ProT-Phe 8 
bond cleavage appears to be catalyzed by at least three enzymes. Evidence to 
support this is as follows. The formation of the complementary peptide products 
ArgX-ProTlPheS-Arg9 is partially inhibited by 1 mM EDTA and completely 
blocked by 1 mM 1,10-phenanthroline (cf. Table III), suggesting the involvement 
of metallopeptidase(s) in ProT-Phe 8 bond cleavage. The partial inhibition of this 
cleavage by endopeptidase 24.11 inhibitor cF-Phe-pAB (Almenoff and Orlow- 
ski, 1983; Matsas et al., 1984) and by ACE inhibitor MK 422 (Patchett et al., 
1980; Matsas et al., 1984) (cf. Table III) indicates the participation of both 
zinc-peptidases, endopeptidase 24.11 and ACE, in ProT-Phe 8 bond hydrolysis. 
PE is a third enzyme seemingly to cleave the same ProT-Phe 8 bond, since the 
PE inhibitor Z-Pro-prol inal  (Wilk and Orlowski, 1983) partially inhibits Bk 
ProT-Phe 8 bond cleavage (determined by Bk-product analysis; Table III) and 
completely blocks PE activity (determined by fluorimetry; Table II). The 
serine-enzyme inhibitor DFP partially inhibits this cleavage and completely 
inhibits PE activity. PCMB strongly blocks ProT-Phe 8 bond cleavage and fully 
inhibits PE activity. PCMB inhibition of ProT-Phe s bond cleavage is partially 
reversed by DTT, which activates PE activity (Table II) and (Greene et al., 1982) 
but inhibits ACE (Softer, 1981) and endopeptidase 24.11 (Almenoft and 
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Orlowski, 1983). EDTA partially inhibits ProT-Phe 8 bond hydrolysis and does 
not affect PE activity, whereas 1,10-phenanthroline strongly blocks both ac- 
tivities. The effects of chelators on neuronal ProT-Phe 8 bond cleavage and PE 
activity are in agreement with those described for brain PE, which is not a 
metalloprotease (cf. reviews by Wilk, 1983; Orlowski, 1983). Neuronal soluble 
PE activity does not behave as a metalloprotease and is activated by Ca 2+ (cf. 
Fig. 4). The activation of PE by dialysis against EDTA (cf. Fig. 4) is possibly due 
to the removal of inhibitory heavy metal. Indeed, some laboratories routinely 
include EDTA in the medium used to assay PE activity (Kato et al., 1980; 
Hersch, 1981). PE is a DTT-activated (Oliveira et al., 1976; Greene et al., 1982) 
serine-endopeptidase (Andrews et al., 1980) specifically inhibited by Z - P r o -  
prolinal (Wilk and Orlowski, 1983). The properties of PE in neuronal perikarya 
homogenate described here are similar to those reported for purified brain PE 
(cf. Wilk, 1983), except for calcium activation. 
Bk inactivation by the neuronal perikarya homogenate through cleavage of 
Pro3-Gly 4 and Gly4-Phe 5 bonds seems to be catalyzed by PE and endopeptidase 
24.11, respectively, as suggested: first by the evidence that both enzymes occur in 
the neuronal homogenate and hydrolyze the Bk ProT-Phe 8 bond (this report); 
and second, by the specificity of purified PE and endopeptidase 24.11, which 
hydrolyze the Bk Pro3-Gly 4 (Orlowski et al., 1979) and Gly4-Phe 5 (Almenoff and 
Orlowski, 1983)bonds, respectively, in addition to the ProT-Phe 8 bond cleavage. 
The use of a time course of Bk-product formation to identify the sites of 
peptide bond cleavage, combined with a peptidase inhibitor paradigm, in which 
the effects of selective inhibitors can be attributed to the blockade of a given bond 
cleavage, leads to the model for the mechanism of Bk inactivation by rat brain 
neuronal perikarya proposed in Fig. 5. Primary cleavages of Bk molecule should 
be distinguished from secondary cleavages of inactivation products. Primary 
cleavage at the Phe5-Ser 6 bond is due almost entirely to the action of a 
calcium-activated thiol-endopeptidase. Cleavage at the Bk Pro7-Phe s bond 
results mainly from the action of endopeptidase 24.11, ACE, and PE. The 
primary cleavages at Pro3-Gly 4 and Glya-Phe 5 bonds appear to result from the 
action of PE and endopeptidase 24.11, respectively. Secondary cleavages of Bk 
inactivation products are clearly demonstrated for Ser6-Arg 9, which is converted 
to Ser6-Pro 7 and PheS-Arg 9 by endopeptidase 24.11, ACE, and PE, and for 
Phe8-Arg 9, which is hydrolyzed by a bestatin-sensitive aminopeptidase. 
Enzymatic degradation has been proposed as a major mechanism for the 
inactivation of neuropeptides. For a peptidase to exert such a role it should fulfill 
some requirements, which include the ability to hydrolyze a peptide bond(s) of its 
potential substrate(s), leading to inactive products, and appropriate localization, 
among others (Lynch and Snyder, 1986; Turner et al., 1985; White et al., 1985). 
The ability of neuronal perikarya ACE and errdopeptidase 24.11 to inactivate Bk 
(this report), taken together with the neurochemical properties of these mem- 
brane peptidase (Turner et al., 1985), suggests that they could play a role in Bk 
neuronal processing. Several possible roles have been proposed for PE such as 
neuropeptide processing (Martins et al., 1980; Oliveira et al., 1976, cf. Wilk, 
1983), participation in intermediate steps of intracellular protein degradation 
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Fig. 5. Model for the mechanism of bradykinin inactivation 
by rat brain neuronal perikarya. Primary cleavages of 
bradykinin molecule are indicated by solid arrows, and 
secondary cleavages of inactivation products by dashed 
arrows. E 24.11, endopeptidase 24.11. 
(Oliveira et al., 1976; Camargo et al., 1979), and participation in neural 
developmental processes (Kato et al., 1980; Martins and De Mello, 1985; DelBel 
et al., 1986; Martins et al., 1987). Peptidases that cleave the Bk PheS-Ser 6 bond 
have been reported in adult brain (Oliveira et al., 1976; Orlowski et al., 1983; 
Camargo et al., 1987; MacDermott et al., 1987) and in neural systems used for 
developmental studies such as the chick retina (Martins and De Mello, 1985) and 
neuro-2a neuroblastoma cells (DelBel et al., 1986), but their similarity to the 
thiol-endopeptidase shown here to occur in neuronal pericarya isolated from the 
developing rat brain is unclear. In addition to suggesting a possible participation, 
if any, of PE and thiol-endopeptidase in neuronal bradykinin inactivation, this 
report shows that bulk isolated neurons from rat brain could be used as a model 
to study neuronal peptide processing. 
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